Anavex Life Sciences (NASDAQ: AVXL) net income
Anavex Life Sciences reported a net loss of $46.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $43.0m. Earnings per share were −$0.54.
Anavex Life Sciences's best year of the last 10 was fiscal 2017. It reported a loss in 10 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$46.4m | — | — | −$0.54 |
| 2024 | −$43.0m | — | — | −$0.52 |
| 2023 | −$47.5m | — | — | −$0.60 |
| 2022 | −$48.0m | — | — | −$0.62 |
| 2021 | −$37.9m | — | — | −$0.54 |
| 2020 | −$26.3m | — | — | — |
| 2019 | −$26.3m | — | — | — |
| 2018 | −$17.3m | — | — | — |
| 2017 | −$13.5m | — | — | — |
| 2016 | −$14.7m | — | — | −$0.42 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Anavex Life Sciences net income compared with its sector
By net income for its latest fiscal year, Anavex Life Sciences ranks 251st of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 249th | Eledon Pharmaceuticals | −$45.6m | — |
| 250th | Precision Biosciences | −$45.7m | −133.4% |
| 251st | Anavex Life Sciences | −$46.4m | — |
| 252nd | Inhibikase Therapeutics | −$48.3m | — |
| 253rd | Shattuck Labs | −$48.8m | −4,880.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Anavex Life Sciences
- How much did Anavex Life Sciences earn in fiscal 2025?
- Anavex Life Sciences reported a net loss of $46.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $43.0m.
- What are the earnings per share of Anavex Life Sciences?
- They were −$0.54 in fiscal 2025, compared with −$0.52 in fiscal 2024.
- Where does Anavex Life Sciences rank in its sector by net income?
- It ranks 251st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Anavex Life Sciences come from?
- From the annual report (Form 10-K) that Anavex Life Sciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Anavex Life Sciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Anavex Life Sciences: the Anavex Life Sciences page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.